ACM
EPZM

AlphaCrest Capital Management’s Epizyme, Inc EPZM Stock Holding History

AlphaCrest Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,100
Closed -$262K – 1387
2021
Q1 		$262K Buy
30,100
+17,000
+130% +$176K 0.01% 1062
2020
Q4 		$142K Sell
13,100
-18,400
-58% -$227K 0.01% 1096
2020
Q3 		$376K Buy
31,500
+18,400
+140% +$246K 0.04% 748
2020
Q2 		$210K Sell
13,100
-52,200
-80% -$911K 0.03% 826
2020
Q1 		$1.01M Buy
+65,300
New +$1.4M 0.12% 268

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

AlphaCrest Capital Management's EPZM Position: Q2 2021 in Review

AlphaCrest Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2021, closing a stake of 30,100 shares — an estimated $262K sold.

AlphaCrest Capital Management first reported a position in EPZM in Q1 2020 and held it in 5 quarters. The position peaked at $1.01M in Q1 2020. 126 funds tracked by Wall St. Rank hold EPZM as of Q2 2021.

  • AlphaCrest Capital Management reported no remaining Epizyme, Inc position as of Q2 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 30,100 Epizyme, Inc shares in Q2 2021, an estimated $262K.
  • AlphaCrest Capital Management first reported a position in Epizyme, Inc in Q1 2020 and held it in 5 quarters.
  • AlphaCrest Capital Management's Epizyme, Inc position peaked at $1.01M in Q1 2020.
  • 126 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2021.

Based on AlphaCrest Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.